Bonde: It was a great, high-risk deal
The Chairman of industry association Dansk Biotek is disappointed to see AbbVie halting development of the Action Pharma-developed asset, ABT-719, but as is the case with most biotech deals there was a high risk associated with the agreement, he says.
BY STEFAN SINGH KAILAY
It is a shame that AbbVie has chosen to discontinue development of Action Pharma-developed asset, ABT-719, but it will not have any impact on how the international community views Danish biotech, says Martin Bonde, Chairman in the industry organization Dansk Biotek.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
One of Denmark’s biggest biotech deals fails to deliver
For abonnenter
“I‘m certainly not bitter, but maybe a bit disappointed”
For abonnenter
